Volume : 08, Issue : 06, June – 2021
Title:
11.NIOSOMES-A NOVEL DRUG DELIVERY SYSTEM
Authors :
G. Pramoda*, S. Geetha, K. Manasa, P. Sindhu, K. Ramya, T. Harila, and K. Padmalatha
Abstract :
Niosomes or non-ionic surfactant vesicles are microscopic lamellar structures formed on admixture of non-ionic surfactant of the alkyl or dialkyl polyglycerol ether class and cholesterol with subsequent hydration in aqueous media. They are vesicular systems similar to liposomes that can be used as carriers of amphiphilic and lipophilic drugs. The method of preparation of niosome is based on liposome technology. The basic process of preparation is the same i.e. hydration by aqueous phase of the lipid phase which may be either a pure surfactant or a mixture of surfactant with cholesterol. After preparing niosomal dispersion, unentrapped drug is separated by dialysis, centrifugation or gel filtration. A method of in-vitro release rate study includes the use of dialysis tubing. Niosomes are promising vehicle for drug delivery and being non-ionic, it is less toxic and improves the therapeutic index of drug by restricting its action to target cells. Niosomes are unilamellar or multilamellar vesicles formed from synthetic non-ionic surfactants. They are very similar to the liposomes. Niosomal drug delivery is potentially applicable to many pharmacological agents for their action against various diseases. Niosomes have shown promise in the release studies and serve as a better option.
Keywords: Niosomes, Vesicular systems, Drug Delivery
Cite This Article:
Please cite this article in press G. Pramoda et al., Niosomes-A Novel Drug Delivery System., Indo Am. J. P. Sci, 2021; 08(06).
Number of Downloads : 10
References:
1. Handjani Vila et al., Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int. J. Cos. Sci. 1: 1979; 303-314.
2. Kemps J. and Crommelin D.A. Hydrolyse van phospholipidic in watering milieu. Pharm Weekbl. 123: 1988; 355-363.
3. Malhotra M. and Jain N.K. Niosomes as Drug Carriers. Indian Drugs, 31(3): 1994; 81-86.
4. Baillie A.J. et al, The preparation and properties of niosomes- Non-ionic surfactant vesicles. J. Pharm. Pharmocol. 1985, 37: 863-868.
5. Rogerson A.et al. The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmocol. 40(5): 1988; 337–342.
6. Baillie A.J., Coombs G.H. and Dolan T.F. Non-ionic surfactant vesicles, niosomes, as delivery system for the anti-leishmanial drug, sodium stribogluconate, J. Pharm.Pharmacol. 38: 1986; 502- 505.
7. Raja Naresh R.A.et al, Anti-inflammatory activity of Noisome encapsulated diclofenac sodium with Tween -85 in Arthritic rats. Ind.J. Pharmocol. 26: 1994; 46-48.
8. Chandra Prakash K.S. et al. Effect of macrophage activation on plasma disposition of niosomal 3 H-Methotrexate in sarcoma-180 bearing mice. J. Drug Target 1, 1993, 143– 145.
9. Rogerson, A et al. The distribution of doxorubicin in mice following administration in niosomes. J. Pharm. Pharmocol. 40, 1988, 337–342.
10. Azmin M.N. et al, The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J. Pharm. Pharmacol. 37, 1985, 237–242.
11. Carter, K.C. et al. The therapeutic effect of sodium stibogluconate in BALB:c mice infected with Leishmania dono6ani is organ dependent. J. Pharm. Pharmacol, 40, 1988, 370– 373.
12. Yoshida H. et al. Niosomes for oral de-livery of peptide drugs. J. Control Rel., 21, 1992, 145– 153.
13. Hofland H. E. J et al. Safety aspects of non-ionic surfactant vesicles-a toxicity study related to the physicochemical characteristics of non-ionic surfactants. J. Pharm. Pharmacol. 44, 1992, 287–294. 1
4. Khan dare J.N., Madhavi G. and Tamhankar B.M. Niosomes novel drug delivery system. The Eastern Pharmacist. 37: 1994; 61-64.
15. Chauhan S. and Luorence M.J. The preparation of polyoxyethylene containing non-ionic surfactant. Vesicles. J. Pharm. Pharmacol. 41: 1989; 6
16. Blazek-Walsh A.I. and Rhodes D.G. SEM imaging predicts quality of niosomes from based proniosomes. J. Pharm. Res. 18: 2001; 656-661.
17. Kaneshina S., Shibata O. and Nakamura. M. The effect of pressure on the mutual solubility of a non-ionic surfactant water system. Bull. Chem. Soc. Japan. 55: 1982, 951-952.
18. Yoshioka T., Stermberg B. and Florence A.T. Preparation and properties of vesicles (niosomes) of sobitan monoesters (Span 20, 40, 60, and 80) and a sorbitan triester (Span 85). Int J Pharm. 105: 1994; 1-6.
19. Gayatri Devi S., Venkatesh P. and Udupa N. Niosomal sumatriptan succinate for nasal administration. Int. J. Pharm. Sci. 62(6), 2000; 479-481.
20. Szoka F.Jr. and Papahadyopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann. Rev. Biophys-Bioeng. 9: 1980; 467-508.
21. Hunter J. A., et al. Vascular systems (niosomes and liposomes) in experimental murine visceral leishmaniasis for delivery of sodium stibogluconate. J. Pharm. Pharmocol. 40 : 1988, 161- 165.
22. Khan dare J.N., Madhavi G. and Tamhankar B.M. Niosomes novel drug delivery system. The Eastern Pharmacist. 37: 1994; 61-64.
23. Azmin M.N.et al, The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J. Pharm. Pharmacol. 37, 1985, 237–242.
24. Rogerson A. et al. Adriamycin-loaded niosomes –drug entrapment, stability and release. J. Microencap. 4, 1987,321.
25. Hu C. and Rhodes D.G. Proniosomes: a novel drug carrier preparation. Int. J. Pharm. 185: 1999; 23-35.
26. Yoshioka T., Sternberg B., Moody M. and Florence A.T. Niosomes from Span surfactants: Relations between structure and form. J. Pharm. Pharmocol. Supp. 44: 1992; 1044.
27. Parthasarathi G. et al, Niosome encapsulated of vincristine sulphate: improved anticancer activity with reduced toxicity in mice. J. Drug Target. 2(2): 1994; 173-182.
28. Arunothayanun P. et al. The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from hexadecyl diglycerol ether. Int. J. Pharm., 2000, 201.
29. Carter K.C., Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J.Pharm. Pharmocol. 41(2): 1989; 87-91.
30. Chandra Prakash K.S. et al, Formulation and evaluation of Methotrexate.